Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Med J Aust. 2011 Jun 6;194(11):567-8. doi: 10.5694/j.1326-5377.2011.tb03105.x.

Abstract

The cost differential between these two drugs is no longer defensible.

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / economics*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Australia
  • Bevacizumab
  • Health Policy*
  • Humans
  • Macular Degeneration / drug therapy*
  • National Health Programs / economics
  • Off-Label Use
  • Randomized Controlled Trials as Topic
  • Ranibizumab

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Ranibizumab